Holen Sie sich die Stockscreener-App
26.85
3.66%
-1.02
Handel nachbörslich:
27.16
0.31
+1.15%
Schlusskurs vom Vortag:
$27.87
Offen:
$27.8
24-Stunden-Volumen:
1.15M
Relative Volume:
1.02
Marktkapitalisierung:
$3.21B
Einnahmen:
$22.57M
Nettoeinkommen (Verlust:
$-212.73M
KGV:
-14.88
EPS:
-1.8045
Netto-Cashflow:
$-142.19M
1W Leistung:
-0.19%
1M Leistung:
-9.41%
6M Leistung:
-25.44%
1J Leistung:
+7.40%
1-Tages-Spanne:
$26.67
$27.97
1-Wochen-Bereich:
$26.43
$28.76
52-Wochen-Spanne:
$23.05
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Firmenname
Newamsterdam Pharma Company Nv
Sektor
Branche
Telefon
35 206 2971
Adresse
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
26.85 | 3.32B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2025-10-20 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-17 | Eingeleitet | Goldman | Neutral |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-06-10 | Eingeleitet | Stifel | Buy |
| 2025-06-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-15 | Eingeleitet | TD Cowen | Buy |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-01-18 | Eingeleitet | Guggenheim | Buy |
| 2024-01-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-30 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Newamsterdam Pharma Company Nv Aktie (NAMS) Neueste Nachrichten
NewAmsterdam (NAMSW) Shares: Moves 3.19% Higher to $16.51; Level Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingFactor Momentum - vinanet.vn
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Acceleration Picks - vinanet.vn
NewAmsterdam (NAMSW) Shares: Shows Minimal Net Change at $16.00 in Latest Trading; Trading Range: Support at $15.20 and Resistance at $16.80 Frame the Range in the Latest SessionSingle Stock ETF - vinanet.vn
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Plunging Sales And Deepening Losses - Sahm
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Bank of America Corp DE - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB - MarketBeat
NewAmsterdam Pharma Warrant (NAMSW) Flat at $16.72 as Range-Bound Trading PersistsVolume Breadth - vinanet.vn
NewAmsterdam Pharma Warrant (NAMSW) Holds Ground at $16.72 as Trading Range TightensAAII Neutral - vinanet.vn
NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal - Stock Titan
NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer - Stock Titan
Newamsterdam Pharma Company N.V. Announces Executive Changes - marketscreener.com
NewAmsterdam Pharma (NAMS) Slips 0.30% to $26.59, Holds Within Established RangeIV Rank - Vinanet
NewAmsterdam Pharma (NAMS) Earnings Losses Raise The Question Of Whether The Stock Is A Bargain - Sahm
NewAmsterdam Pharma (NAMS) Edges Higher to $27.83 as Range-Bound Trading PersistsBreakout Stock Alerts - vinanet.vn
Did NewAmsterdam Pharma’s (NAMS) Sharp Revenue Drop and Wider Loss Just Shift Its Investment Narrative? - webull.com
How Newamsterdam Pharma Company N.v. (NAMS) Affects Rotational Strategy Timing - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring an 83.24% Potential Upside in Biotech - DirectorsTalk Interviews
HC Wainwright Issues Pessimistic Outlook for NAMS Earnings - MarketBeat
Equities Analysts Offer Predictions for NAMS FY2027 Earnings - MarketBeat
NewAmsterdam Pharma grants 28,000 inducement share options at $27.79 to new hires - Bitget
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
(NAMSW) Volatility Zones as Tactical Triggers - Stock Traders Daily
FMR LLC and Abigail Johnson report 10.3M-share Pharma Company NV (NAMS) stake - Stock Titan
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
NewAmsterdam Pharma Company N.V. reports results for the quarter ended June 30Earnings Summary - TradingView
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - The Manila Times
NewAmsterdam reports $64.1M Q2 net loss, $678.3M cash; CHMP recommends obicetrapib approval - TradingView
NewAmsterdam Pharma Co N.V. Q2 2026: Revenue $3.7M, EPS $(0.52) — 10-Q Summary - TradingView
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - 富途牛牛
NAMS Q2'26 Earnings: revenue estimate is 1.88M USD - TradingView
NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring An 86.77% Upside Potential - DirectorsTalk Interviews
NewAmsterdam Pharma Warrant (NAMSW) Holds Ground at $17.19 as Traders Eye Key Support and Resistance LevelsMAMA Signal - Vinanet
NewAmsterdam Pharma Q1 2026 Earnings: EPS Beat Narrower Than Expected, Stock Edges DownBuyback Announcement Report - dars.gov.et
(NAMS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
NewAmsterdam Pharma Company N.V. $NAMS Stake Boosted by Stempoint Capital LP - MarketBeat
NewAmsterdam Pharma to Host Investor Day on August 5, 2026 - GlobeNewswire
NewAmsterdam Pharma Warrants (NAMSW) Decline 6.58% as Selling Pressure MountsVWAP Breakout - dars.gov.et
Louise Frederika Kooij Sells 105,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - MarketBeat
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NAMS|NewAmsterdam Pharma Company NV|Price:30.190|Chg%:+0.550 - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Income Statement - TradingKey
TradingKey - TradingKey
NewAmsterdam Pharma says EU CHMP backs approval of Ubeslo, Evlarco cholesterol drugs - Bitget
NewAmsterdam Pharma Company NV (NAMS) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Cash Flow - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Finanzdaten der Newamsterdam Pharma Company Nv-Aktie (NAMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):